Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01818232 · ClinicalTrials.gov registry record · Phase 1
Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01818232 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT01818232, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase 1 study is to evaluate the pharmacokinetics (PK), metabolism, routes and extent of elimination of a single oral dose of 400 mg \[14C\]LX4211 to healthy male subjects
Interventions
- DRUG [14C]-LX4211
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01818232
The ClinicalTrials.gov registry entry for NCT01818232 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-LX4211 is the first listed.
NCT01818232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01818232 about?
NCT01818232 is a clinical study titled "Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects". This phase 1 study is to evaluate the pharmacokinetics (PK), metabolism, routes and extent of elimination of a single oral dose of 400 mg \[14C\]LX4211 to healthy male subjects
What is the current status of trial NCT01818232?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-03. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01818232?
The interventions under investigation include: [14C]-LX4211 (DRUG).
Who is sponsoring clinical trial NCT01818232?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.